Mind Medicine (MindMed) Inc N.MMED.WR

Primary Symbol: MNMD Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc > It is already worth 2 BILLION CAD

<< Previous

Bullboard Posts

Next >>

Post by SouthernTierTomon Jun 25, 2021 10:54am

442 Views

Post# 33450213

It is already worth 2 BILLION CAD

So the article you suggest says 20 BILLION??

WOW .... I haven't dropped ACID since the late 60's, who'd thunk it ? ; - )

And now with the mesacaline and ecstacy studies...maybe 30 or 40 BILLION..wowzers!!

The math seems "stretched" ...does "dropping" help make the numbers seem more "doable"?

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec